Printer Friendly

Statins, Nonstatin therapies can help to slump the soaring cholesterol.

Islamabad -- According to recent study, Statins should remain the first-line therapy for lowering cholesterol and reducing the risk of cardiovascular disease, but if they cannot be tolerated, nonstatin therapies may be just as beneficial.

Statins are drugs that block a cholesterol-producing enzyme in the liver called HMG-CoA reductase. This lowers the production of low-density lipoprotein (LDL) cholesterol - the "bad" cholesterol that can increase the risk of heart attack, stroke, and heart disease.

Study co-author Dr. Marc S. Sabatine, of Brigham and Women's Hospital at Harvard Medical School in Boston, MA, and colleagues note that the clinical benefits of using statins to lower LDL cholesterol are widely accepted, largely due to the high-quality evidence of their safety and efficacy in clinical trials.

The team notes that trials specifically investigating how PCSK9 inhibitors affect cardiovascular outcomes have yet to be completed, so data for these drugs to date were assessed separately and compared with data for therapies that increase LDL receptor expression.

The results of the analysis revealed that statins and nonstatin therapies that increase LDL receptor expression were both similarly effective for reducing LDL cholesterol and reducing the risk of major cardiovascular events.

With both types of therapies, every 1 millimole per liter (39 milligrams per deciliter) reduction in LDL cholesterol represented a 23 percent decrease in the risk of major cardiovascular events, the team reports.

According to Dr. Sabatine and colleagues, their results "deserve careful consideration in light of the strength of the available trial evidence for different types of therapies."

The authors add:

"As per current guidelines, when tolerated, statins should be the first-line therapy given the large reductions observed for LDL-C [LDL cholesterol], the excellent safety profile, the demonstrated clinical benefit, and low cost (now that most are generic).

However, the data in the present meta-regression analysis raise the possibility that other interventions, especially those that ultimately act predominantly through upregulation of LDL receptor expression, may provide additional options and may potentially be associated with the same relative clinical benefit per each 1 millimole per liter reduction in LDL-C."

COPYRIGHT 2016 Asianet-Pakistan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Frontier Star (Northwest Frontier Province, Pakistan)
Date:Sep 30, 2016
Previous Article:Foreign Currency Account Scheme.
Next Article:Cell reprogramming discovery can help in treating eye diseases.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters